These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 20864901)

  • 1. A systematic review of the effect of CYP3A5 genotype on the apparent oral clearance of tacrolimus in renal transplant recipients.
    Barry A; Levine M
    Ther Drug Monit; 2010 Dec; 32(6):708-14. PubMed ID: 20864901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Effect of Weight and CYP3A5 Genotype on the Population Pharmacokinetics of Tacrolimus in Stable Paediatric Renal Transplant Recipients.
    Prytuła AA; Cransberg K; Bouts AH; van Schaik RH; de Jong H; de Wildt SN; Mathôt RA
    Clin Pharmacokinet; 2016 Sep; 55(9):1129-43. PubMed ID: 27138785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetic modelling and design of a Bayesian estimator for therapeutic drug monitoring of tacrolimus in lung transplantation.
    Monchaud C; de Winter BC; Knoop C; Estenne M; Reynaud-Gaubert M; Pison C; Stern M; Kessler R; Guillemain R; Marquet P; Rousseau A
    Clin Pharmacokinet; 2012 Mar; 51(3):175-86. PubMed ID: 22339449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measurement and compartmental modeling of the effect of CYP3A5 gene variation on systemic and intrarenal tacrolimus disposition.
    Zheng S; Tasnif Y; Hebert MF; Davis CL; Shitara Y; Calamia JC; Lin YS; Shen DD; Thummel KE
    Clin Pharmacol Ther; 2012 Dec; 92(6):737-45. PubMed ID: 23073208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CYP3A5*3 Genetic Polymorphism and Tacrolimus Concentration in Myanmar Renal Transplant Patients.
    Htun YY; Swe HK; Saw TM
    Transplant Proc; 2018 May; 50(4):1034-1040. PubMed ID: 29731062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CYP3A5 polymorphisms and their effects on tacrolimus exposure in an ethnically diverse South African renal transplant population.
    Muller WK; Dandara C; Manning K; Mhandire D; Ensor J; Barday Z; Freercks R
    S Afr Med J; 2020 Jan; 110(2):159-166. PubMed ID: 32657689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetic analysis and dosing guidelines for tacrolimus co-administration with Wuzhi capsule in Chinese renal transplant recipients.
    Jing Y; Kong Y; Hou X; Liu H; Fu Q; Jiao Z; Peng H; Wei X
    J Clin Pharm Ther; 2021 Aug; 46(4):1117-1128. PubMed ID: 33768546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative performance of oral midazolam clearance and plasma 4β-hydroxycholesterol to explain interindividual variability in tacrolimus clearance.
    Vanhove T; de Jonge H; de Loor H; Annaert P; Diczfalusy U; Kuypers DR
    Br J Clin Pharmacol; 2016 Dec; 82(6):1539-1549. PubMed ID: 27501475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis.
    Zuo XC; Ng CM; Barrett JS; Luo AJ; Zhang BK; Deng CH; Xi LY; Cheng K; Ming YZ; Yang GP; Pei Q; Zhu LJ; Yuan H; Liao HQ; Ding JJ; Wu D; Zhou YN; Jing NN; Huang ZJ
    Pharmacogenet Genomics; 2013 May; 23(5):251-61. PubMed ID: 23459029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of cytochrome P450 3A5 (CYP3A5) genetic polymorphism on the pharmacokinetics of the prolonged-release, once-daily formulation of tacrolimus in stable renal transplant recipients.
    Glowacki F; Lionet A; Hammelin JP; Labalette M; Provôt F; Hazzan M; Broly F; Noël C; Cauffiez C
    Clin Pharmacokinet; 2011 Jul; 50(7):451-9. PubMed ID: 21528942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polymorphism of the CYP3A5 gene and its effect on tacrolimus blood level.
    Nair SS; Sarasamma S; Gracious N; George J; Anish TS; Radhakrishnan R
    Exp Clin Transplant; 2015 Apr; 13 Suppl 1():197-200. PubMed ID: 25894154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CYP3A5 genotype had no impact on intrapatient variability of tacrolimus clearance in renal transplant recipients.
    Spierings N; Holt DW; MacPhee IA
    Ther Drug Monit; 2013 Jun; 35(3):328-31. PubMed ID: 23666583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients.
    Press RR; Ploeger BA; den Hartigh J; van der Straaten T; van Pelt J; Danhof M; de Fijter JW; Guchelaar HJ
    Ther Drug Monit; 2009 Apr; 31(2):187-97. PubMed ID: 19258929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetics of tacrolimus in adult kidney transplant patients: impact of CYP3A5 genotype on starting dose.
    Bergmann TK; Hennig S; Barraclough KA; Isbel NM; Staatz CE
    Ther Drug Monit; 2014 Feb; 36(1):62-70. PubMed ID: 24089074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in renal transplant recipients on a new once-daily formulation.
    Benkali K; Rostaing L; Premaud A; Woillard JB; Saint-Marcoux F; Urien S; Kamar N; Marquet P; Rousseau A
    Clin Pharmacokinet; 2010 Oct; 49(10):683-92. PubMed ID: 20818834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequencies and Association of CYP3A5 Polymorphism With Tacrolimus Concentration Among Renal Transplant Recipients in Vietnam.
    Xuan NT; Hop VQ; Kien TQ; Toan PQ; Thang LV; Binh HT; Van Tran P; Minh HT; Man PT; Cuong HX; Ben NH; Phuong NM; Linh NT; Linh NT; Dung VD; Quyen LTB; Hang DTT; Su HX
    Transplant Proc; 2022 Oct; 54(8):2140-2146. PubMed ID: 36085176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients.
    Fukudo M; Yano I; Yoshimura A; Masuda S; Uesugi M; Hosohata K; Katsura T; Ogura Y; Oike F; Takada Y; Uemoto S; Inui K
    Pharmacogenet Genomics; 2008 May; 18(5):413-23. PubMed ID: 18408564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CYP3A5 polymorphism in Mexican renal transplant recipients and its association with tacrolimus dosing.
    García-Roca P; Medeiros M; Reyes H; Rodríguez-Espino BA; Alberú J; Ortiz L; Vásquez-Perdomo M; Elizondo G; Morales-Buenrostro LE; Mancilla Urrea E; Castañeda-Hernández G
    Arch Med Res; 2012 May; 43(4):283-7. PubMed ID: 22704849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of donor
    Wheeler C; Masimirembwa C; Mthembu B; Botha J; Scholefield J; Fabian J
    S Afr Med J; 2024 Apr; 114(3b):e1367. PubMed ID: 39041443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of Tacrolimus Exposure by CYP3A5 Genotype and Exposure of Co-Administered Everolimus in Japanese Renal Transplant Recipients.
    Kagaya H; Niioka T; Saito M; Inoue T; Numakura K; Yamamoto R; Akamine Y; Habuchi T; Satoh S; Miura M
    Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29547545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.